U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Name Type Language
SIFALIMUMAB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
MDX-1103
Preferred Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERFERON ALPHA SUBTYPES) HUMAN MONOCLONAL MEDI-545 .GAMMA.1 HEAVY CHAIN (219-215')-DISULFIDE WITH HUMAN MONOCLONAL MEDI-545 .KAPPA. LIGHT CHAIN, DIMER (225-225'':228-228'')-BISDISULFIDE
Common Name English
MEDI-545
Code English
SIFALIMUMAB [USAN]
Common Name English
Sifalimumab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERFERON .ALPHA.) (HUMAN MONOCLONAL MEDI-545 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI-545 .KAPPA.-CHAIN, DIMER
Common Name English
sifalimumab [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
Code System Code Type Description
DRUG BANK
DB12773
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
NCI_THESAURUS
C95061
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
USAN
UU-130
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
INN
9135
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
CAS
1006877-41-3
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
WIKIPEDIA
SIFALIMUMAB
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
SMS_ID
100000175128
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
FDA UNII
XOY1YA7RMC
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
ChEMBL
CHEMBL1743069
Created by admin on Wed Apr 02 07:45:52 GMT 2025 , Edited by admin on Wed Apr 02 07:45:52 GMT 2025
PRIMARY
ACTIVE MOIETY
SIFALIMUMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966